Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$149.76 USD

149.76
1,714,060

+5.62 (3.90%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Aug 11, 2023

by Zacks Equity Research

Companies in The News Are: DDS,MFC,ILMN,G

Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

by Zacks Equity Research

Illumina (ILMN) shipped 109 NovaSeq X instruments in the second quarter, boosting its supply capacity to more than 390 instruments for fiscal 2023.

Illumina (ILMN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 1,500% and 1.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Soars 3.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Illumina (ILMN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Illumina's (ILMN) Latest Launch to Boost Genomics Analysis

by Zacks Equity Research

Illumina's (ILMN) DRAGEN v4.2 is expected to improve the identification of genetic disease causes, drug discovery and population genomics.

LGND or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LGND vs. ILMN: Which Stock Is the Better Value Option?

LGND vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research

LGND vs. ILMN: Which Stock Is the Better Value Option?

Here's Why You Should Retain Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Illumina (ILMN) on solid long-term growth potential in the oncology space.

Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger

by Zacks Equity Research

Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.

LGND or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LGND vs. ILMN: Which Stock Is the Better Value Option?

Illumina's (ILMN) New AI Tool to Predict Genomics Disease

by Zacks Equity Research

Illumina's (ILMN) PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.

Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?

by Zacks Equity Research

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Repligen (RGEN) Up 2.7% Since Last Earnings Report?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Illumina (ILMN) to Present Real-World CGP Data at ASCO Meet '23

by Zacks Equity Research

At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?

by Zacks Equity Research

Sector ETF report for RYH

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

Illumina (ILMN) Progresses in Pathogen Genomic Technologies

by Zacks Equity Research

Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.

Illumina (ILMN) Q1 Earnings Beat Estimates, Margins Contract

by Zacks Equity Research

Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.

Illumina (ILMN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Illumina (ILMN) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 300% and 2.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

EXEL or ILMN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Illumina (ILMN) Partners With Henry Ford Health for NGS Test

by Zacks Equity Research

Illumina (ILMN) collaborates with Henry Ford Health to conduct a series of studies that is likely to focus on the genetic drivers of cardiovascular disease.

Illumina (ILMN) to Expand Genomics Capacity With New Pact

by Zacks Equity Research

Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.